Red Light Holland Corp. reports developments in legal regulated botanical wellness, natural-product therapeutic research, and regulated consumer products. The Ontario-based company owns Filament Health Corp., a clinical-stage natural botanical therapeutics developer with GMP production capabilities, FDA regulatory engagement, a global clinical research footprint, and PEX010, a patented botanical research compound therapeutic candidate.
Company news commonly covers peer-reviewed clinical data, research-institution distribution of PEX010, exclusive licenses to trial data and related intellectual property, and R&D initiatives based on consensual data collection. Updates also address commercial activities in Europe and North America, including regulated consumer product sales in the Netherlands' legal market and home cultivation kits sold through B2B and direct-to-consumer channels.
Rhelion Life Sciences (TRUFF) subsidiary Filament Health signed a licence and supply agreement with UCSF for a Phase 2 psilocybin trial. Filament will supply PEX010, its botanical psilocybin drug candidate, for PRISM, studying methamphetamine use disorder among people living with HIV.
The trial will enroll 30 participants with moderate to severe methamphetamine use disorder, randomly assigned equally to a single monitored 25 mg or 5 mg dose. The 5 mg dose is the active comparator; participants, care providers, investigators and outcome assessors will be masked to dose. Primary outcomes are feasibility, acceptability, safety and tolerability. The trial is expected to begin in November 2026 at Zuckerberg San Francisco General Hospital. UCSF's Dr. Nicky J. Mehtani is the sponsor; Filament is not responsible for trial conduct. The National Institute on Drug Abuse supports the work.
Rhelion Life Sciences (TRUFF), through subsidiary Filament Health, shipped PEX010 to the University of Calgary for a Phase 2 PTSD trial.
The PsiPTSD study (NCT06885996) will evaluate psilocybin-assisted therapy for chronic post-traumatic stress disorder in adult survivors of intimate partner violence. Dr. Chantel Debert leads the study. It is her second University of Calgary trial to use PEX010, following a Phase 2b study of persisting symptoms after concussion (NCT06615908). PEX010 is Filament's botanical psilocybin drug candidate.
Rhelion Life Sciences (TRUFF) expanded Filament Health's supply and licence agreement with the University G. d'Annunzio of Chieti-Pescara for the TEMPO trial in Italy.
The amendment increases supply of PEX010 25 mg capsules after the trial's participant count rose during regulatory review. TEMPO, a trial of psilocybin for treatment-resistant depression, was authorized under the European Union Clinical Trials Regulation. The University sponsors and conducts the trial. Filament supplies PEX010 and provides regulatory support for the trial and the drug's release for European Union use.
Rhelion Life Sciences (TRUFF) announced that its wholly owned subsidiary Filament Health has been issued a new Canadian patent titled “Psychoactive Alkaloid Extraction and Composition with Controlled Dephosphorylation,” covering aspects of its natural psilocybin technology used to make lead drug candidate PEX010.
The grant expands what the company describes as the most extensive natural psilocybin patent estate, which now totals 78 issued patents across 13 patent families in regions including the United States, Canada, Australia, Israel, Mexico and Europe. The patent estate protects the extraction, purification, stabilization, standardized compositions and delivery methods for PEX010. PEX010 is GMP manufactured and supplied in standardized 1, 5 and 25 mg doses, with a 0.5 mg dose planned, and is used to support more than 80 research and compassionate access studies worldwide.
Rhelion Life Sciences (TRUFF), through wholly owned subsidiary Filament Health, has shipped its patented psilocybin drug candidate PEX010 to Bruyère Health Research Institute for a Phase 3, multi‑site, double‑blind, placebo‑controlled trial in palliative care.
The PSYCHED‑PAL study will compare microdose psilocybin with placebo in 120 people with advanced illness and psychological distress, recruited from inpatient, outpatient and community palliative care settings across seven Canadian sites. Participants will take small daily, non‑hallucinogenic doses that do not require accompanying psychotherapy, aimed at being practical for end‑of‑life care. Bruyère Health Research Institute sponsors the trial; Filament is not responsible for its conduct.
The Phase 3 trial builds on a Phase I/II study using PEX010 that reported microdose psilocybin as safe, feasible and potentially effective, with no serious adverse effects. PEX010 is supplied in standardized 1, 5 and 25 mg doses, with 0.5 mg to follow, and supports more than 80 research studies worldwide. Rhelion completed its acquisition of Filament and its 77‑patent portfolio on April 30, 2026.
Rhelion Life Sciences (TRUFF) announced a supply and licensing agreement for its psilocybin candidate PEX010 with CHDR in the Netherlands.
Through wholly owned subsidiary Filament Health, Rhelion will supply PEX010 capsules in 1 mg and 5 mg doses, plus matching placebo, and provide regulatory support for a CHDR-sponsored study of low and medium dose psilocybin under the EU Clinical Trials Regulation. The study, conducted with Leiden University’s PRSM Lab and supported by Norrsken Mind, remains subject to regulatory and ethics approval. PEX010 is a patented, GMP-manufactured botanical psilocybin available in standardized 1, 5 and 25 mg doses, with 0.5 mg planned, and is used in more than 80 research studies worldwide. Rhelion completed the acquisition of Filament, including 77 issued patents across 13 families, on April 30, 2026.
Rhelion Life Sciences (TRUFF) announced that its wholly owned subsidiary, Filament Health, has signed a supply and licensing agreement with the University of Southern California, on behalf of the Keck School of Medicine, to provide PEX010, Filament's patented, standardized, GMP-manufactured botanical psilocybin drug candidate. PEX010 will be used as the investigational drug in a trial of psilocybin-assisted mindfulness therapy, including a clinical depression cohort, although Filament is not the sponsor and is not responsible for trial conduct.
The company highlights that PEX010 is produced via proprietary extraction, purification and stabilization methods designed to ensure consistent composition across doses, studies and sites, and notes that Filament supplies and supports more than 80 academic and philanthropic research studies worldwide. Rhelion completed the acquisition of Filament, including 77 issued patents across 13 patent families and PEX010, on April 30, 2026.
Rhelion Life Sciences (TRUFF) announced that Sarit Hashkes, President of wholly owned subsidiary Filament Health, will deliver oral comments at the FDA public hearing on “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs” on September 14, 2026.
The hearing, convened by the FDA’s Center for Drug Evaluation and Research, is gathering input on development, evaluation and potential future therapeutic use of psychedelic drugs. Filament is one of the organizations speaking during the public comment period, with remarks expected around 3:40 p.m. ET. The event will be streamed live on FDA’s YouTube channel.
The release also highlights Filament’s lead drug candidate PEX010, a patented, standardized, GMP-manufactured botanical psilocybin product, and notes Rhelion’s April 30, 2026 acquisition of Filament and its portfolio of 77 issued patents across 13 patent families. PEX010 is investigational and not approved by FDA or any other regulator.
Rhelion Life Sciences (TRUFF) announced that subsidiary Filament Health has begun planning a stability program for IBEX011, its naturally derived, GMP ibogaine drug candidate, in response to growing demand for standardized ibogaine for regulated clinical research.
IBEX011 is described as a Nagoya Protocol-compliant, total-alkaloid iboga extract produced via Filament’s proprietary extraction, purification and stabilization methods, the same platform used for psilocybin candidate PEX010. Rhelion links this initiative to rising U.S. interest in ibogaine, including federal and state research funding and policy actions. Filament already supplies PEX010 to more than 80 academic and philanthropic studies worldwide and holds 77 issued patents across 13 patent families. Ibogaine remains a Schedule I substance and IBEX011 has not been authorized for clinical trials.
Rhelion Life Sciences (TRUFF) announced that wholly owned subsidiary Filament Health has shipped its patented psilocybin drug candidate PEX010 from Canada to Austin Health in Melbourne for PSI-PHY, an investigator-initiated pilot trial of psilocybin-assisted physiotherapy in adults with refractory motor functional neurological disorder (FND), sponsored by The University of Melbourne and funded by the Australian Government’s Medical Research Future Fund.
PSI-PHY is the first study to use PEX010 in a movement disorder and, to the company’s knowledge, the first anywhere to combine a psychedelic with physiotherapy. Filament supplies standardized GMP-manufactured PEX010 capsules in 1, 5 and 25 mg doses, with a 0.5 mg dose planned, enabling dose-comparison designs using consistent material across study arms. Filament is the investigational drug supplier but is not the sponsor and is not responsible for trial conduct.